Description
Aessoa Global with Lidocaine Hyaluronic Acid Dermal Filler for Fine to Moderate Wrinkle Correction
Aessoa Global with Lidocaine is a high-purity, hyaluronic-acid-based dermal filler formulated for aesthetic soft-tissue augmentation and wrinkle correction. This device comprises a monophasic cross-linked hyaluronic acid gel at approximately 24 mg/ml with 0.3% lidocaine hydrochloride, a local anaesthetic included to improve patient comfort during injection. Delivered via a sterile, prefilled 1.0 ml syringe, the filler is designed primarily for mid-dermis placement, where water-binding properties aid skin texture improvement and hydration . Its viscoelastic properties (approx. 100–200 Pa·s) facilitate smooth extrusion and moulding at treatment sites.
The inclusion of lidocaine assists in analgesia without altering the fundamental rheologic behaviour of the hyaluronic acid gel. Aessoa Global is indicated for fine to moderate wrinkle correction, contour refinement, and aesthetic enhancement when used by qualified and trained medical professionals in accordance with the official instructions for use (IFU) and appropriate aseptic technique.
What Aessoa Global with Lidocaine Is Similar To
Aessoa Global with Lidocaine belongs to the widely used class of hyaluronic acid (HA) dermal fillers, functioning through volumetric support and water binding to improve the appearance of wrinkles and facial contours. In this category, products such as Teosyal Puresense Global Action also utilise cross-linked HA with lidocaine to provide comfort-assisted injections for lines and contouring. Both types aim to replace lost volume and integrate within the dermal matrix to support smoother skin topography.
Differences among HA fillers typically relate to HA concentration, cross-linking chemistry, viscosity, and manufacturer-specified indications. Aessoa Global’s formulation is positioned for fine to moderate superficial wrinkles and hydration enhancement, whereas some other fillers in the same family may be optimised for deeper folds or larger volumetric augmentation. As with all injectable gels, clinician technique, anatomical placement depth, and product rheology influence clinical outcomes.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
Based on publicly available professional descriptions:
-
Fine to moderate facial wrinkles
-
Periorbital lines (around the eyes)
-
Perioral lines
-
Lip contouring
-
Texture improvement / hydration enhancement
treatment areas not explicitly provided by manufacturer in official IFU.
Usage / Administration
Official manufacturer IFU details are not publicly available online; therefore, the following are based on label descriptions from authorised distributors:
-
Injection depth: mid dermis
-
Volume per point / injection site: not provided by manufacturer
-
Needle gauge: recommended 30 G needle (distributor suggestion; not official IFU)
-
Frequency / number of sessions: not provided by manufacturer
-
Professional-use disclaimer: administered only by qualified medical professionals under aseptic conditions.
Ingredient List
-
Hyaluronic acid (HA): ~24 mg/ml (cross-linked)
-
Lidocaine hydrochloride: ~0.3%
-
Excipients / buffer: not provided by manufacturer
Presentation & Longevity
-
Presentation: 1 × 1 ml prefilled syringe
-
Shelf life: not provided by manufacturer
-
Treatment duration / longevity: up to 12–18 months based on clinical experience and distributor information (may vary per patient)
Safety Notes / Contraindications
Public IFU details are limited; include standard clinical cautions:
-
Use is contraindicated in patients with known hypersensitivity to hyaluronic acid, lidocaine, or any component.
-
Avoid treatment in areas with active skin infection or inflammation.
-
Not for use in individuals with severe allergy history or systemic conditions without qualified medical assessment.
-
Device for single-use only; do not reuse.
Regulatory Status
-
Aessoa fillers including Global are widely CE-marked in EU markets according to distributor declarations.
-
Regulatory classification not specified in public documentation; verify on the product pack or manufacturer’s IFU.
FAQ
1:What is Aessoa Global with Lidocaine and how does it work?
Aessoa Global with Lidocaine is a hyaluronic acid-based dermal filler intended for mid-dermis injection. It binds to water molecules within the skin to improve texture and hydration while replacing volume to reduce fine and moderate wrinkles. Lidocaine serves as a local anaesthetic to support injection comfort.
2: Which areas can Aessoa Global be used on?
Professional descriptions indicate use for fine facial lines, periorbital and perioral wrinkles, and lip contour definition. Official manufacturer IFU details on specific zones are not published; clinicians should follow training and IFU guidance.
3: How long do results typically last?
Distributor information commonly cites longevity of up to 12–18 months, though individual results may vary based on metabolism, treatment area, and product placement.
4: Is lidocaine included and why?
Yes — Aessoa Global contains approximately 0.3% lidocaine, which is intended to reduce discomfort during injection without altering the filler’s rheologic characteristics.
5: How does Aessoa Global compare to other HA fillers?
Like other HA fillers, Aessoa Global provides soft-tissue support through water binding and volume replacement. Differences among products relate to HA concentration, cross-linking, and gel viscosity, which influence behaviour and clinical use. This product is positioned for fine to moderate lines rather than heavy volumisation.
